SCHEMBL21360101

SCHEMBL21360101

COCCNc1ccncn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 10/20 0.57
CYP2C19 P33261 6/20 0.57
CYP3A4 P08684 5/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
CYP2C9 P11712 3/20 0.57
CYP2D6 P10635 3/20 0.57
HTT P42858 1/20 0.57
HCAR3 P49019 1/20 0.49
ALDH1A1 P00352 5/20 0.48
HSD17B10 Q99714 3/20 0.48
ALOX15 P16050 3/20 0.48
CLK4 Q9HAZ1 3/20 0.48
HIF1A Q16665 1/20 0.48
USP2 O75604 1/20 0.48
APEX1 P27695 1/20 0.48
CASP7 P55210 1/20 0.48
KDM4E B2RXH2 4/20 0.44
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
GLA P06280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16160635 0.90 CYP1A2 (0.55) CYP1A2CYP2C19CYP3A4SMN1; SMN2CYP2C9
SCHEMBL5554310 0.79 SMN1; SMN2 (0.54) CYP1A2CYP2C19CYP3A4SMN1; SMN2CYP2C9
SCHEMBL30195099 0.79 SMN1; SMN2 (0.54) CYP1A2CYP2C19CYP3A4SMN1; SMN2CYP2C9
SCHEMBL3647775 0.76 POLB (0.60) CYP1A2CYP2C19CYP2C9CYP2D6HCAR3
SCHEMBL29980727 0.76 POLB (0.60) CYP1A2CYP2C19CYP2C9CYP2D6HCAR3
SCHEMBL2638413 0.76 TLR8 (0.56) CYP1A2CYP2C19CYP3A4SMN1; SMN2CYP2C9
SCHEMBL30593302 0.76 TLR8 (0.56) CYP1A2CYP2C19CYP3A4SMN1; SMN2CYP2C9
SCHEMBL11225383 0.76 HCAR3 (0.54) CYP1A2CYP2C19CYP3A4CYP2D6HCAR3
SCHEMBL32678784 0.76 SMN1; SMN2 (0.50) CYP1A2CYP2C19CYP3A4SMN1; SMN2CYP2C9
SCHEMBL22110996 0.76 SMN1; SMN2 (0.50) CYP1A2CYP2C19CYP3A4SMN1; SMN2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed
WO-2019177375-A1 2, 4, 5-SUBSTITUTED PYRIMIDINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT 포로노이바이오 주식회사 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR CYP1A2 1905/4885CYP2C19 1243/4885CYP3A4 2997/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR CYP1A2 1905/4885CYP2C19 1243/4885CYP3A4 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.